Helocyte
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Gansevoort St Fl 9, New York City, New...Phone Number
(212) 554-4520Website
www.helocyte.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Helocyte
Helocyte, Inc. is a clinical-stage company founded by Fortress Biotech, Inc. that specializes in developing innovative immunotherapies aimed at preventing and treating cancer and infectious diseases, such as cytomegalovirus (CMV) and human immunodeficiency virus (HIV). The company focuses on advancing its pipeline of therapies to address significant medical needs. Helocyte targets healthcare providers and institutions involved in oncology and infectious disease management. Through its research and development efforts, Helocyte aims to contribute to improved patient outcomes in these critical areas.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Helocyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Helocyte, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Helocyte had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Helocyte has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Helocyte has new funding data
Congratulate Masked Content for being promoted to Masked Content at Helocyte
Earning: See what the market has to say on Helocyte recently announced quarterly report
Product Launch: Get notified when Helocyte launches new products
Check out if Helocyte is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Helocyte as Masked Content
Find more new buyers
Compare Similar Companies to Helocyte
Compare insights from companies similar to Helocyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Helocyte
<$5M
1-10
Private
$7M
2015
N/A
Company Profile Activity
Activity Insights
Helocyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Helocyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Helocyte.
Helocyte financials insights
Gather financial insights about Helocyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$3M
Debt
$4M
Helocyte Tech Stack
A closer look at the technologies used by Helocyte
See more technologies
Helocyte News & Media
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIVHelocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipientsHelocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplantStudy Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Helocyte
Sign Up For FreeTo access detailed company insights
Helocyte, Inc. is a clinical-stage company founded by Fortress Biotech, Inc. that specializes in developing innovative immunotherapies aimed at preventing and treating cancer and infectious diseases, such as cytomegalovirus (CMV) and human immunodeficiency virus (HIV). The company focuses on advancing its pipeline of therapies to address significan... Read More
